Reading SBC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SBC free→Reading SBC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SBC free→NASDAQIndustrialsConsulting ServicesSnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, but earnings quality is fragile, reported profits aren't backed by cash. Management's recent track record has been fairly steady, and the company has a capital-friendly stance. Risk is high, and the sector backdrop is a headwind, which may impact performance compared to sector peers that are above typical. Peer multiples imply a price about 68% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk, as it trades below peer multiples while earnings quality is fragile. This analysis is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 6 valuation methods, at three horizons. Current price $2.99. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $2.91 SBC trades at 7× p/e, below its 23× p/e peer median. Our $9.43 fair value sits above the price; medium confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price sits about 69% below a flat-multiple fair value; not enough history to forecast a comparison. This describes what's priced in, not a forecast of the move.
Only weak execution quality — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Industrials names rated strong grew net income 69% of the time over the next year (vs 58% for the rest of the cohort, n=3696).
Over the trailing year it converted 0.78x of net income into operating cash flow. Historically, Industrials names rated fragile grew net income 56% of the time over the next year (vs 60% for the rest of the cohort, n=3333).
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates.
8 material management or governance events in the past 24 months, led by M&A activity. Historically, Industrials names rated neutral grew net income 59% of the time over the next year (vs 60% for the rest of the cohort, n=1113).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.12 → $0.12 (+0.0% / 30d). 1 raised, 1 cut, 4 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
0 positive, 0 negative / 30d.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$165.
How much price usually moves either way.
On a bad day, this stock has moved -$604.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $4,920.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If revenue growth picks up, it could signal a recovery for SBC and its peers.
Confirms:Three-year revenue growth in the industrial sector rises above 7%.
Disproves:Three-year revenue growth stays below 5%.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for SBC yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 14, 2026, SBC Medical Group Holdings Incorporated (the “Company”), issued a press release announcing its results for the quarter ended March 31, 2026. The press release is attached as Exhibit 99.1 and is incorporated herein by reference. The information furnished under Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwi…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Research & Consulting Services.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
SBC SBC Medical Group Holdings, Inc. | Above typical Show detailsSector percentile: 83 of 100 | inexpensive | high |
VRSK Verisk Analytics | Above typical Show detailsSector percentile: 84 of 100 | fair | elevated |
EFX Equifax | Above typical Show detailsSector percentile: 86 of 100 | fair | elevated |
TRU TransUnion | Above typical Show detailsSector percentile: 93 of 100 | inexpensive | moderate |
BAH Booz Allen Hamilton | Above typical Show detailsSector percentile: 96 of 100 | inexpensive | elevated |
Not investment advice. As of 2026-06-16.
via XLI
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
SBC aims to enter the U.S. medical aesthetics market through strategic partnerships and investments.
Newly stated in 2026-Q1. SBC announced a strategic minority equity investment in OrangeTwist, marking its entry into the U.S. medical aesthetics market. This strategic move aligns with the company's growth objectives, but financial impact is yet to be seen.
“The Transaction marks the Company’s formal entry into the U.S. medical aesthetics market.”
SBC's Board authorized a $20 million share repurchase program to optimize capital allocation.
Newly stated in 2025-Q4. SBC announced a $20 million share repurchase program, but no buyback activity is reported in the financials. The program's execution and impact on capital allocation remain to be seen.
“The Company’s Board of Directors has authorized a $20.0 million share repurchase program.”
SBC aims to sustain its positive net income trajectory as part of its financial strategy.
Stated in 3 of last 3 quarters. Net income for 2026-Q1 was $11.3M, down from $14.2M in 2025-Q4 and $12.8M in 2025-Q3. Despite the decline, SBC maintains a positive net income trajectory, indicating ongoing financial stability.
“Net income for 2026-Q1 was $11.3M.”
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 14, 2026, Mike Sayama, an independent director of SBC Medical Group Holdings Incorporated (the “Company”), notified the Company that he would not seek re-election at the Company’s forthcoming 2026 Annual Meeting of Stockholders (the “2026 AGM”). The Company’s board of directors has reduced the size of the board of directors to four members,…
Entry into a Material Definitive Agreement. On April 19, 2026, SBC Medical Group Holdings Incorporated (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) by and among the Company, Dr. Yoshiyuki Aikawa, the Company’s CEO and Chairman of the board of directors, as selling stockholder (the “Selling Stockholder”) and Maxim Group LLC, as representative of the several underwriters named in Schedule 1 thereto (the “Underwriters”), relating to an underwritten offeri…
Results of Operations and Financial Condition. On March 27, 2026, SBC Medical Group Holdings Incorporated (the “Company”), issued a press release announcing its fourth quarter and full year 2025 financial results. The press release is attached as Exhibit 99.1 and is incorporated herein by reference. The information furnished under Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), o…
Other Events. On January 5, 2026, the Company announced the completion of a strategic minority equity investment in OrangeTwist, a U.S.-based MedSpa chain, and entered into a structured collaboration framework with OrangeTwist and its institutional shareholders, Hildred Capital and Athyrium Capital (collectively, the “Transaction”). The Transaction marks the Company’s formal entry into the U.S. medical aesthetics market and represents an initial step in the Company’s multi-phase global expans…
“Net income was $14.2M.”
“Net income was $12.8M.”